INGN Keeps announcing new and old data, but that's OK as long as it helps the stock .<g>
Bernard
Introgen Continues to Advance INGN 007 for the Treatment of Cancer
Monday June 6, 12:00 pm ET
Pre-Clinical Pharmacology and Safety Data Presented at the Annual Meeting of the American Society of Gene Therapy
ST. LOUIS, June 6 /PRNewswire-FirstCall/ -- Introgen Therapeutics Inc. (Nasdaq: INGN - News) and its collaborators presented new data from its INGN 007 program in oncolytic viruses for the treatment of cancer this past weekend at the American Society of Gene Therapy 8th Annual Meeting.
Three abstracts were presented by Introgen collaborator William S.M. Wold, Ph.D., chairman of the Department of Microbiology and Immunology at the Saint Louis University School of Medicine and founder and chief executive officer of VirRx, describing the activity of Introgen's portfolio of oncolytic viruses, as well as preclinical pharmacology and safety data with INGN 007 its leading oncolytic viral product candidate.
Results show that INGN 007 has a favorable safety profile and significantly inhibits primary tumor growth as well as metastatic disease. The oncolytic virus data were presented in abstracts #1021, #1022 and #1023.
"We have been impressed with the efficacy of INGN 007 that significantly inhibited tumor growth and metastasis in these studies. Importantly, the safety of INGN 007 was similar to that of other adenoviral products that are derived from a naturally occurring and benign virus to which many people have been exposed," said Louis A. Zumstein, Ph.D., Introgen's associate vice president of Research. Dr. Zumstein continued, "The preclinical models also tolerated a very high dose of INGN 007, suggesting a good margin of safety with this product. Taken together, these data provide a strong rationale for advancing INGN 007 and our other oncolytic viruses into the clinic and support their potential utility as a novel approach to treating cancer."
Snip
biz.yahoo.com |
